Diploma: a blue-chip set for strong growth
Diploma, whose niche products include seals and fasteners, serves an array of growth markets. Should you invest?
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
You are now subscribed
Your newsletter sign-up was successful
Want to add more newsletters?
Twice daily
MoneyWeek
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Four times a week
Look After My Bills
Sign up to our free money-saving newsletter, filled with the latest news and expert advice to help you find the best tips and deals for managing your bills. Start saving today!
A small number of British firms have achieved sustained profitable growth using a combination of organic growth and bolt-on acquisitions, which are then developed much further. Diploma (LSE: DPLM) is a good example. I first recommended Diploma in MoneyWeek in April 2019, when the shares stood at 1,550p. That article pointed out that the share price had risen two-and-a-half times from 608p in autumn 2015 and suggested that there was plenty of potential for further growth.
This duly occurred: the recent share price is 4,140p, so the shares have risen almost threefold in just over five years, or nearly 22% per year with annual dividends on top of that. Diploma is a company in the FTSE 100 index with a market value of around £5.6 billion and 2023 turnover of £1.2 billion. The firm offers plenty of scope for further growth, with revenue up 52% between 2021 and 2023. Its three divisions all aim to achieve market-leading positions in their niches.
Diploma’s three arms are life sciences (comprising 17% of sales), seals (37%) and controls (45%). They all provide products coupled with services. These products and associated services are critical to customers, but of relatively low cost, so they are purchased from clients’ operating rather than capital budgets. Controls includes specialised fasteners (for aerospace, for instance) and adhesives; seals includes components and fittings for pneumatic pumps – both stock and custom-made, and often for mission-critical applications; life sciences includes technology-enabled products for surgery and endoscopy, along with diagnostic equipment for clinical laboratories and food safety testing.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Diploma's acquisitions drive profits
Diploma has a strong mergers-and-acquisitions (M&A) pipeline diversified by sector, size and geography. The firm made six acquisitions worth a total of £284 million in the first half of the year to 31 March 2024. This sum exceeded the total seen in the two full previous financial years. The largest purchase this year was America’s Peerless Aerospace Fasteners for £236 million. It will accelerate organic growth through product and geographical expansion and should add 8% to Diploma’s earnings per share (EPS) in the year after the takeover. The second-biggest acquisition was UK-based Plastics & Rubber Group Holdings (PAR) for £38 million. It will add scale to the seals-and-gaskets activities and deliver an additional 1% of EPS.
Both Peerless and PAR are founder-owned businesses with great records of organic growth and business models that match Diploma’s strategy of building high-quality businesses for sustainable organic growth. Diploma operates a decentralised business model that encourages entrepreneurship and focuses on core, scalable business lines that can be developed with organic growth supplemented by bolt-on acquisitions.
This strategy has driven the company’s profitable growth, with revenue more than doubling to £1.2 billion between 2020 and 2023, operating profit rising by 2.6 times over that period and the dividend climbing from 20.5p to 55.3p a share. Diploma serves a diversified set of growing markets, including clinical diagnostics, electrification, industrial automation, infrastructure, renewables, water management, energy and civil aerospace. This tempers the impact of a slowdown in any one market.
Diploma uses return on adjusted trading capital employed (ROATCE) as a key financial measure, which is more demanding than the usual gauge of profitability, return on capital employed (ROCE). ROATCE is the pre-tax return on total capital – fixed and working plus intangibles and goodwill, including goodwill previously written off against retained earnings. ROATCE, therefore, covers capital spent on acquisitions. Diploma’s average ROATCE for the past five years has been 19%.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Highly qualified (BSc PhD CPhys FInstP MIoD) expert in R&D management, business improvement and investment analysis, Dr Mike Tubbs worked for decades on the 'inside' of corporate giants such as Xerox, Battelle and Lucas. Working in the research and development departments, he learnt what became the key to his investing; knowledge which gave him a unique perspective on the stock markets.
Dr Tubbs went on to create the R&D Scorecard which was presented annually to the Department of Trade & Industry and the European Commission. It was a guide for European businesses on how to improve prospects using correctly applied research and development.
He has been a contributor to MoneyWeek for many years, with a particular focus on R&D-driven growth companies.
-
UK interest rates live: rates held at 3.75%The Bank of England’s Monetary Policy Committee (MPC) met today to decide UK interest rates, and voted to hold rates at their current level
-
MoneyWeek Talks: The funds to choose in 2026Podcast Fidelity's Tom Stevenson reveals his top three funds for 2026 for your ISA or self-invested personal pension
-
Three companies with deep economic moats to buy nowOpinion An economic moat can underpin a company's future returns. Here, Imran Sattar, portfolio manager at Edinburgh Investment Trust, selects three stocks to buy now
-
Should you sell your Affirm stock?Affirm, a buy-now-pay-later lender, is vulnerable to a downturn. Investors are losing their enthusiasm, says Matthew Partridge
-
Why it might be time to switch your pension strategyYour pension strategy may need tweaking – with many pension experts now arguing that 75 should be the pivotal age in your retirement planning.
-
Beeks – building the infrastructure behind global marketsBeeks Financial Cloud has carved out a lucrative global niche in financial plumbing with smart strategies, says Jamie Ward
-
Saba Capital: the hedge fund doing wonders for shareholder democracyActivist hedge fund Saba Capital isn’t popular, but it has ignited a new age of shareholder engagement, says Rupert Hargreaves
-
Silver has seen a record streak – will it continue?Opinion The outlook for silver remains bullish despite recent huge price rises, says ByteTree’s Charlie Morris
-
Investing in space – finding profits at the final frontierGetting into space has never been cheaper thanks to private firms and reusable technology. That has sparked something of a gold rush in related industries, says Matthew Partridge
-
Star fund managers – an investing style that’s out of fashionStar fund managers such as Terry Smith and Nick Train are at the mercy of wider market trends, says Cris Sholto Heaton
